📊 BETRF Key Takeaways
Is BetterLife Pharma Inc. (BETRF) a Good Investment?
BetterLife Pharma is a pre-revenue pharmaceutical company in severe financial distress with minimal cash generation and unsustainable burn rate. With only $2.9K in revenue against $4.0M in operating losses and $3.6M negative free cash flow, the company faces imminent liquidity crisis given its $406.9K cash position and 0.15x current ratio.
BetterLife Pharma Inc.'s fundamentals are extremely weak, with negligible revenue, deeply negative operating margins, and persistent cash burn that far exceeds its cash balance. The improvement in net income appears low quality because operating losses remain severe, while the very weak liquidity position raises substantial financing and going-concern risk.
Why Buy BetterLife Pharma Inc. Stock? BETRF Key Strengths
- Minimal debt burden with 0.00x debt-to-equity ratio reducing financial leverage risk
- Positive stockholders equity of $3.4M provides some balance sheet cushion
- Operating as a pharmaceutical company in high-value sector with potential for future value creation if pipeline succeeds
- No meaningful long-term debt reduces balance-sheet leverage risk
- Positive stockholders' equity provides some residual balance-sheet support
- Net loss improved year over year, indicating reduced bottom-line pressure versus the prior period
BETRF Stock Risks: BetterLife Pharma Inc. Investment Risks
- Critically low liquidity with current ratio of 0.15x and only $406.9K cash against substantial operating burn
- Severe revenue deficit with $2.9K revenue insufficient to cover any operational costs, indicating pre-commercialization stage
- Unsustainable cash burn of $3.6M annually will deplete remaining cash reserves in approximately 1.4 months at current run rate
- Extreme negative margins (operating margin -138191%, net margin -20579%) with no path to profitability visible
- Stale financial data from October 2021 raises uncertainty about current financial position and runway
- Zero insider purchases in last 90 days suggests lack of management confidence
- Revenue base is effectively nonexistent, making the business model unproven at this stage
- Operating cash outflow is heavy relative to cash on hand, implying near-term funding risk
- Current and quick ratios of 0.15x indicate severe liquidity stress and limited financial flexibility
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash runway to assess solvency timeline
- Revenue growth from pharmaceutical pipeline advancement or partnerships
- Capital raise announcements or debt financing to extend operational runway
- Clinical trial progress and regulatory milestones for drug candidates
- Operating expense reduction initiatives or restructuring plans
- Quarterly operating cash burn relative to cash balance
- Revenue growth and progress toward sustainable operating margin improvement
BetterLife Pharma Inc. (BETRF) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BETRF Profit Margin, ROE & Profitability Analysis
BETRF vs Healthcare Sector: How BetterLife Pharma Inc. Compares
How BetterLife Pharma Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is BetterLife Pharma Inc. Stock Overvalued? BETRF Valuation Analysis 2026
Based on fundamental analysis, BetterLife Pharma Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
BetterLife Pharma Inc. Balance Sheet: BETRF Debt, Cash & Liquidity
BETRF Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: BetterLife Pharma Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.10 indicates the company is currently unprofitable.
BETRF Revenue Growth, EPS Growth & YoY Performance
BETRF Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2019 | $5.0M | -$3.5K | N/A |
| Q3 2018 | $5.0M | $204.6K | $0.00 |
| Q1 2018 | $5.0M | -$259.4K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BetterLife Pharma Inc. Dividends, Buybacks & Capital Allocation
BETRF SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for BetterLife Pharma Inc. (CIK: 0001464165)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BETRF
What is the AI rating for BETRF?
BetterLife Pharma Inc. (BETRF) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BETRF's key strengths?
Claude: Minimal debt burden with 0.00x debt-to-equity ratio reducing financial leverage risk. Positive stockholders equity of $3.4M provides some balance sheet cushion. ChatGPT: No meaningful long-term debt reduces balance-sheet leverage risk. Positive stockholders' equity provides some residual balance-sheet support.
What are the risks of investing in BETRF?
Claude: Critically low liquidity with current ratio of 0.15x and only $406.9K cash against substantial operating burn. Severe revenue deficit with $2.9K revenue insufficient to cover any operational costs, indicating pre-commercialization stage. ChatGPT: Revenue base is effectively nonexistent, making the business model unproven at this stage. Operating cash outflow is heavy relative to cash on hand, implying near-term funding risk.
What is BETRF's revenue and growth?
BetterLife Pharma Inc. reported revenue of $2.9K.
Does BETRF pay dividends?
BetterLife Pharma Inc. does not currently pay dividends.
Where can I find BETRF SEC filings?
Official SEC filings for BetterLife Pharma Inc. (CIK: 0001464165) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BETRF's EPS?
BetterLife Pharma Inc. has a diluted EPS of $-0.07.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BETRF a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, BetterLife Pharma Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BETRF stock overvalued or undervalued?
Valuation metrics for BETRF: ROE of -17.5% (sector avg: 15%), net margin of -20,579.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BETRF stock in 2026?
Our dual AI analysis gives BetterLife Pharma Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BETRF's free cash flow?
BetterLife Pharma Inc.'s operating cash flow is $-3.6M, with capital expenditures of N/A. FCF margin is -121,805.5%.
How does BETRF compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -20,579.3% (avg: 12%), ROE -17.5% (avg: 15%), current ratio 0.15 (avg: 2).